Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.58 |
| ▸ | TUBB | P07437 | 1/20 | 0.58 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.58 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.58 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.58 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.58 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.58 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4423384 | 0.90 | GPR119 (0.59) | LMNASMN1; SMN2TSHRALDH1A1ALOX15 | |
| SCHEMBL12580567 | 0.90 | LMNA (0.62) | LMNASMN1; SMN2TSHRHTTMEN1 | |
| SCHEMBL4419288 | 0.89 | LMNA (0.59) | LMNASMN1; SMN2TSHRHTTMEN1 | |
| SCHEMBL31260537 | 0.89 | HDAC4 (0.56) | LMNASMN1; SMN2TSHRALDH1A1ALOX15 | |
| SCHEMBL12580564 | 0.89 | HDAC4 (0.56) | LMNASMN1; SMN2TSHRALDH1A1HTT | |
| SCHEMBL4414448 | 0.89 | GPR119 (0.56) | LMNASMN1; SMN2TSHRALDH1A1ALOX15 | |
| SCHEMBL4414338 | 0.89 | GPR119 (0.56) | LMNASMN1; SMN2TSHRALDH1A1ALOX15 | |
| SCHEMBL2901393 | 0.89 | TUBB4A (0.58) | LMNASMN1; SMN2TSHRALOX15MAPK1 | |
| SCHEMBL1653518 | 0.89 | TUBB4A (0.60) | LMNASMN1; SMN2TSHRALOX15MAPK1 | |
| SCHEMBL193106 | 0.89 | GRM5 (0.71) | LMNASMN1; SMN2TSHRALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | claimed |
| US-20260048047-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | SCRIPPS RESEARCH INST (US) | 2026-02-19 | — | — | US | disclosed |
| WO-2024030121-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-02-08 | — | — | WO | disclosed |
| CN-116178361-A | Preparation of piperidine bisoxadiazole and piperidine amino thiazole substituted antitumor curcumenol derivatives and application thereof in antitumor | 华东理工大学 | 2023-05-30 | — | — | CN | disclosed |
| US-8338599-B2 | Compounds having a potentiating effect on the activity of ethionamide and uses thereof | INSTITUT PASTEUR DE LILLE (FR) | 2012-12-25 | — | — | US | disclosed |
| US-8207199-B2 | Azole compound | ASTELLAS PHARMA INC. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-8207199-B2 | Azole compound | ASTELLAS PHARMA INC. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20110136823-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | INSTITUT PASTEUR DE LILLE (FR) | 2011-06-09 | — | — | US | disclosed |
| US-20110118311-A1 | AZOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110118311-A1 | AZOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2308869-A1 | AZOLE COMPOUND | Astellas Pharma Inc. (JP) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010007966-A1 | AZOLE COMPOUND | アステラス製薬株式会社 (JP) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118311-A1 | AZOLE COMPOUND | FAAH, FAAH2, TRPV1 | LMNA 4326/4885SMN1; SMN2 1891/4885TSHR 4788/4885 |
| US-20090325924-A1 | GPCR Agonists | GPR119, GCGR, GPR27 | LMNA 4210/4885SMN1; SMN2 2663/4885TSHR 222/4885 |
| US-20110136823-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | EPX, PGLS, ENPEP | LMNA 1439/4885SMN1; SMN2 4639/4885TSHR 2305/4885 |
| US-20260048047-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | FNTB, PDE7A, TBL3 | LMNA 1838/4885SMN1; SMN2 4875/4885TSHR 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.